TRIAD1 is negatively regulated by the MDM2 E3 ligase

Bae,Seunghee; Jung,Jin  Hyuk; An,In-Sook; Kim,Ok-Yeoun; Lee,Myoung Joo; Lee,Jae  Ho; Park,In-Chul; Lee,Su-Jae; An,Sungkwan

doi:10.3892/or.2012.2005

November 2012 Volume 28 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November 2012 Volume 28 Issue 5

Full Size Image

Article

TRIAD1 is negatively regulated by the MDM2 E3 ligase

Authors:
- Seunghee Bae
- Jin Hyuk Jung
- In-Sook An
- Ok-Yeoun Kim
- Myoung Joo Lee
- Jae Ho Lee
- In-Chul Park
- Su-Jae Lee
- Sungkwan An
View Affiliations / Copyright

Affiliations: Molecular-Targeted Drug Research Center, Konkuk University, Gwangjin-gu, Seoul 143-701, Republic of Korea, Korea Institute for Skin and Clinical Sciences, Konkuk University, Gwangjin-gu, Seoul 143-701, Republic of Korea, Laboratory of Molecular Oncology, Cheil General Hospital and Women's Healthcare Center, Kwandong University, College of Medicine, Jung-gu, Seoul 100-380, Republic of Korea, Laboratory of Functional Genomics, Korea Institute of Radiological and Medical Sciences, Nowon-gu, Seoul 139-706, Republic of Korea, Department of Chemistry, Hanyang University, Seongdong-gu, Seoul 133-791, Republic of Korea
Pages: 1924-1928
|
Published online on: August 31, 2012

https://doi.org/10.3892/or.2012.2005
Expand metrics +

Abstract

Two RING fingers and DRIL1 (TRIAD1) is a proapoptotic protein that promotes p53 activation in several cancer cell lines, including MCF7, U2OS and A549 cells. In this study, we demonstrated that TRIAD1 is a novel ubiquitination target for proteasome-dependent degradation by murine double minute 2 (MDM2). TRIAD1 was found to interact with and be ubiquitinated by MDM2. RNA interference against MDM2 increased endogenous TRIAD1 protein stability. The functional study results suggested that TRIAD1 degradation by MDM2 suppresses TRIAD1-mediated cell growth. These data suggested a novel negative regulatory mechanism of TRIAD1 via MDM2 E3 ligase ubiquitination.

View Figures

View References

1	Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar
2	Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI
3	Ardley HC and Robinson PA: E3 ubiquitin ligases. Essays Biochem. 41:15–30. 2005. View Article : Google Scholar
4	van der Reijden BA, Erpelinck-Verschueren CA, Lowenberg B and Jansen JH: TRIADs: a new class of proteins with a novel cysteine-rich signature. Protein Sci. 8:1557–1561. 1999.PubMed/NCBI
5	Marteijn JA, van Emst L, Erpelinck-Verschueren CA, et al: The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. Blood. 106:4114–4123. 2005. View Article : Google Scholar : PubMed/NCBI
6	Jung JH, Lee SM, Bae S, et al: Triad 1 induces apoptosis by p53 activation. FEBS lett. 584:1565–1570. 2010. View Article : Google Scholar : PubMed/NCBI
7	Wang H, Bei L, Shah CA, Horvath E and Eklund EA: HoxA10 influences protein ubiquitination by activating transcription of ARIH2, the gene encoding Triad1. J Biol Chem. 286:16832–16845. 2011. View Article : Google Scholar : PubMed/NCBI
8	Chu MC, Selam FB and Taylor HS: HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther. 3:568–572. 2004. View Article : Google Scholar : PubMed/NCBI
9	Chi XZ, Kim J, Lee YH, et al: Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res. 69:8111–8119. 2009. View Article : Google Scholar : PubMed/NCBI
10	Dai MS, Shi D, Jin Y, et al: Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem. 281:24304–24313. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jin Y, Zeng SX, Lee H and Lu H: MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J Biol Chem. 279:20035–20043. 2004. View Article : Google Scholar : PubMed/NCBI
12	Leng RP, Lin Y, Ma W, et al: Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 112:779–791. 2003. View Article : Google Scholar : PubMed/NCBI
13	Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
14	Faderl S, Kantarjian HM, Estey E, et al: The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 89:1976–1982. 2000. View Article : Google Scholar : PubMed/NCBI
15	Fulci G, Labuhn M, Maier D, et al: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene. 19:3816–3822. 2000. View Article : Google Scholar : PubMed/NCBI
16	Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D and Bieche I: Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 67:3963–3969. 2007. View Article : Google Scholar
17	Midgley CA, Desterro JM, Saville MK, et al: An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 19:2312–2323. 2000. View Article : Google Scholar : PubMed/NCBI
18	Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725–734. 1998. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

TRIAD1 is negatively regulated by the MDM2 E3 ligase

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles